Developer docs
API playgroundTry for free, no card

Search company profiles

Cardio Flow

Full company profile

uuid0002tfy

Namestring
Cardio Flow
Legal namestring
Cardio Flow, Inc.
Websiteurl
cardioflow.net
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Cardio Flow, Inc. is a privately held, commercial-stage medical device company headquartered in St. Paul, Minnesota (with a physical office in Blaine, MN), founded in 2014. The company develops, manufactures, and sells the FreedomFlow Orbital Atherectomy Platform, a catheter-based system that uses diamond-coated spheres in a proprietary spiral geometry leveraging angular momentum physics to sand away plaque blockages in peripheral arteries. The platform treats vessels from 2 mm to 8 mm in diameter with a single device and is offered with multiple driveshaft configurations (5 Fr 3-sphere, 5 Fr 5-sphere, 6 Fr 5-sphere), both pneumatically and electrically powered user handles, and a control module and tubing set. The portfolio also includes the FDA-cleared FreedomFlow Peripheral Guidewire.

The company received FDA 510(k) clearance for the atherectomy platform in October 2023 and completed its first commercial cases the same month at Cardiovascular Institute of the South. Cardio Flow generates revenue through direct hardware sales of single-use catheters, driveshafts, guidewires, and reusable handle/power-supply components. It goes to market exclusively in the United States via a direct field sales force targeting interventional cardiologists, interventional radiologists, and vascular surgeons practicing in hospitals, ambulatory surgery centers (ASCs), and office-based labs (OBLs). Key customers include CIS and Advanced Cardiac & Vascular Centers for Amputation Prevention, the latter led by Cardio Flow's own Chief Medical Officer Dr. Jihad Mustapha. The leadership team includes multiple former executives of Cardiovascular Systems, Inc. (now Abbott), including co-founder Gary Petrucci and former CEO Michael Kallok, who bring deep atherectomy domain and IP expertise (17+ U.S. patents attributable to Kallok).

Short descriptiontext

Cardio Flow is a U.S. medical device company that develops and sells the FreedomFlow Orbital Atherectomy Platform, a catheter-based system for treating peripheral artery disease (PAD) in hospitals, ASCs, and office-based labs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSaint Paul, United States
HQ citystring
Saint Paul
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
orbital atherectomy devices, peripheral vascular devices, atherectomy catheters, medical device manufacturing, vascular intervention equipment
Industry1 code
PRIMARYHLAHAFAE
Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
Product category
Peripheral Vascular Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1FreedomFlow Orbital Atherectomy Platform Sales
TypeHardware Sales
Description

Cardio Flow generates revenue through the sale of its FreedomFlow atherectomy platform products, including catheters, driveshafts (3-sphere and 5-sphere variants in 5 Fr and 6 Fr sizes), control modules, tubing sets, user handles (pneumatic and electric), and peripheral guidewires. The platform is designed for single-device use treating multiple blockages.

cardioflow.net
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1FreedomFlow
Description

FreedomFlow is an orbital atherectomy platform for treating peripheral artery disease (PAD). The platform uses diamond-coated spheres in a spiral geometry to clear plaque blockages in peripheral arteries, treating vessels from 2mm to 8mm in diameter.

cardioflow.net
Core offering1 text field

Cardio Flow develops and sells the FreedomFlow Orbital Atherectomy Platform, a catheter-based system that uses diamond-coated spheres in a spiral geometry leveraging angular momentum physics to treat peripheral artery disease in vessels from 2 mm to 8 mm in diameter. The platform includes multiple driveshaft configurations (5 Fr 3-sphere, 5 Fr 5-sphere, and 6 Fr 5-sphere), pneumatic and electric-powered user handles, a control module, and the complementary FreedomFlow Peripheral Guidewire, targeting hospitals, ambulatory surgery centers, and office-based labs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Treats vessels from 2mm in the ankle to 8mm in the hip with a single device
+2 more records
Product overview1 text field

Cardio Flow is a commercial-stage medical device company that develops minimally invasive peripheral vascular products for treating Peripheral Artery Disease (PAD). The company's product portfolio centers on the FreedomFlow Orbital Atherectomy Platform, a catheter-based system that uses diamond-coated spheres in a spiral geometry powered by angular momentum to sand away plaque blockages. The platform includes multiple driveshaft options (5 Fr 3-sphere, 5 Fr 5-sphere, and 6 Fr 5-sphere) treating vessels from 2 mm to 8 mm in diameter, along with both pneumatic and electric-powered user handles and a control module. Complementing the atherectomy platform is the FreedomFlow Peripheral Guidewire, a stainless steel core-to-tip guidewire with silicone coating that received FDA clearance in June 2022. All products are designed, developed, and manufactured in the USA (Minnesota).

Product and service2 records
1FreedomFlow Orbital Atherectomy Platform
CategoryAtherectomy Catheter System
Description

Catheter-based orbital atherectomy platform for treating peripheral artery disease (PAD) in hospitals, ambulatory surgery centers, and office-based labs. Uses diamond-coated spheres in a spiral geometry that creates a rotational vortex to sand away plaque blockages, treating vessels from 2 mm to 8 mm in diameter with a single device. Includes 5 Fr 3-sphere, 5 Fr 5-sphere, and 6 Fr 5-sphere driveshaft options, pneumatic and electric-powered user handles, and a control module with tubing set.

2FreedomFlow Peripheral Guidewire
CategoryPeripheral Guidewire
Description

Stainless steel core-to-tip peripheral guidewire with fixed distal-spring coil and silicone coating on the distal 200 cm. Designed to provide exceptional support for diagnostic and therapeutic devices used in treating plaque blockages in arteries both above and below the knee. The 0.014-inch core-to-tip design delivers superior torque transmission and precise control, enabling delivery of multiple interventional devices on a single guidewire.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2023-10-30
Description

CIS performed the first commercial cases of the FreedomFlow Orbital Atherectomy Platform. Drs. Craig Walker, Pradeep Nair, and McCall Walker conducted the initial procedures on patients with complex arterial anatomy, multiple blockages, and extensive calcium including chronic total occlusions.

2Advanced Cardiac & Vascular Centers for Amputation Prevention
Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2022-06-02
Description

Dr. Jihad Mustapha, Director and Chief Medical Officer of Cardio Flow, is also President and CEO of Advanced Cardiac & Vascular Centers for Amputation Prevention. The centers serve as a key clinical site for FreedomFlow device testing and the first commercial case with the peripheral guidewire was performed there by Dr. Mustapha.

cardioflow.net
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Avinger
TypeDirect peer
Description

Small-cap developer of lumivascular (OCT-guided) directional atherectomy (Pantheris, Tigereye) for PAD. Closely comparable in size, stage, and product focus to Cardio Flow, with similar U.S. sales channel.

TypeBroad incumbent
Description

Sells the Auryon atherectomy system (laser-based, acquired from Eximo Medical) within a broader vascular access and oncology portfolio. Direct competitor in peripheral atherectomy, particularly for below-the-knee lesions.

TypeEmerging player
Description

Focuses on venous thromboembolism and peripheral thrombectomy (FlowTriever, ClotTriever), increasingly expanding into arterial PAD/CLTI procedures. Adjacent competitor for the same interventional cardiologist and vascular surgeon customers.

TypeBroad incumbent
Description

Through the HawkOne directional atherectomy system (acquired from Covidien/eV3) Medtronic is a leading player in peripheral atherectomy. Offers a much broader portfolio of PAD devices, with global reach Cardio Flow lacks.

TypeDirect peer
Description

Makes the Indigo CAT RX aspiration system and Lightning Bolt/Storm peripheral thrombectomy portfolio - an emerging direct competitor in the PAD/CLTI interventional space where Cardio Flow also operates.

TypeBroad incumbent
Description

Acquired CSI in 2023 and now sells the Diamondback 360 orbital atherectomy line alongside a broad peripheral vascular portfolio (stents, balloons, closure). Competes head-to-head with FreedomFlow via the same mechanism Cardio Flow's founders originally commercialized.

TypeBroad incumbent
Description

Sells the Rotacarett rotational atherectomy system as part of a large peripheral vascular franchise (angioplasty balloons, stents, thrombectomy). Competes with FreedomFlow in U.S. cath labs and OBLs treating PAD.

TypeBroad incumbent
Description

Markets laser atherectomy (formerly Spectranetics' Turbo-Elite and ExciLite) within a broad IGT/peripheral franchise. Competes with FreedomFlow in PAD/CLI procedures, especially where calcium modification is required.

TypeDirect peer
Description

CSI pioneered orbital atherectomy with the Diamondback 360 and was acquired by Abbott in 2023. Cardio Flow's founders (Petrucci, Kallok) co-founded and led CSI, and FreedomFlow is the spiritual successor using a similar orbital mechanism - the closest possible direct peer.

TypeDirect peer
Description

Develops and commercializes peripheral vascular intervention products including drug-coated balloons and the Sublime guidewire line. Targets the same cath lab, ASC, and OBL sites of care as FreedomFlow.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cardio Flow

Peripheral Vascular Medical Devicescardioflow.net

Cardio Flow is a U.S. medical device company that develops and sells the FreedomFlow Orbital Atherectomy Platform, a catheter-based system for treating peripheral artery disease (PAD) in hospitals, ASCs, and office-based labs.

What Cardio Flow does

Cardio Flow, Inc. is a privately held, commercial-stage medical device company headquartered in St. Paul, Minnesota (with a physical office in Blaine, MN), founded in 2014. The company develops, manufactures, and sells the FreedomFlow Orbital Atherectomy Platform, a catheter-based system that uses diamond-coated spheres in a proprietary spiral geometry leveraging angular momentum physics to sand away plaque blockages in peripheral arteries. The platform treats vessels from 2 mm to 8 mm in diameter with a single device and is offered with multiple driveshaft configurations (5 Fr 3-sphere, 5 Fr 5-sphere, 6 Fr 5-sphere), both pneumatically and electrically powered user handles, and a control module and tubing set. The portfolio also includes the FDA-cleared FreedomFlow Peripheral Guidewire.

The company received FDA 510(k) clearance for the atherectomy platform in October 2023 and completed its first commercial cases the same month at Cardiovascular Institute of the South. Cardio Flow generates revenue through direct hardware sales of single-use catheters, driveshafts, guidewires, and reusable handle/power-supply components. It goes to market exclusively in the United States via a direct field sales force targeting interventional cardiologists, interventional radiologists, and vascular surgeons practicing in hospitals, ambulatory surgery centers (ASCs), and office-based labs (OBLs). Key customers include CIS and Advanced Cardiac & Vascular Centers for Amputation Prevention, the latter led by Cardio Flow's own Chief Medical Officer Dr. Jihad Mustapha. The leadership team includes multiple former executives of Cardiovascular Systems, Inc. (now Abbott), including co-founder Gary Petrucci and former CEO Michael Kallok, who bring deep atherectomy domain and IP expertise (17+ U.S. patents attributable to Kallok).

Cardio Flow firmographics

Firmographics
Name
Cardio Flow
Legal name
Cardio Flow, Inc.
Website
https://cardioflow.net
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
Cardio Flow is a U.S. medical device company that develops and sells the FreedomFlow Orbital Atherectomy Platform, a catheter-based system for treating peripheral artery disease (PAD) in hospitals, ASCs, and office-based labs.
Ownership category
akta.pro rank

Cardio Flow industry classification

Industry
Product category
Peripheral Vascular Medical Devices
akta.pro industry
PRIMARYHLAHAFAE
Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Orbital atherectomy devices
  • Peripheral vascular devices
  • Atherectomy catheters
  • Medical device manufacturing
  • Vascular intervention equipment

Where Cardio Flow is headquartered

Location

Headquarters

HQ city
Saint Paul
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Cardio Flow business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. FreedomFlow Orbital Atherectomy Platform Sales: Cardio Flow generates revenue through the sale of its FreedomFlow atherectomy platform products, including catheters, driveshafts (3-sphere and 5-sphere variants in 5 Fr and 6 Fr sizes), control modules, tubing sets, user handles (pneumatic and electric), and peripheral guidewires. The platform is designed for single-device use treating multiple blockages.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Cardio Flow product offering

Product offering

Core offering

Cardio Flow develops and sells the FreedomFlow Orbital Atherectomy Platform, a catheter-based system that uses diamond-coated spheres in a spiral geometry leveraging angular momentum physics to treat peripheral artery disease in vessels from 2 mm to 8 mm in diameter. The platform includes multiple driveshaft configurations (5 Fr 3-sphere, 5 Fr 5-sphere, and 6 Fr 5-sphere), pneumatic and electric-powered user handles, a control module, and the complementary FreedomFlow Peripheral Guidewire, targeting hospitals, ambulatory surgery centers, and office-based labs.

Product overview

Cardio Flow is a commercial-stage medical device company that develops minimally invasive peripheral vascular products for treating Peripheral Artery Disease (PAD). The company's product portfolio centers on the FreedomFlow Orbital Atherectomy Platform, a catheter-based system that uses diamond-coated spheres in a spiral geometry powered by angular momentum to sand away plaque blockages. The platform includes multiple driveshaft options (5 Fr 3-sphere, 5 Fr 5-sphere, and 6 Fr 5-sphere) treating vessels from 2 mm to 8 mm in diameter, along with both pneumatic and electric-powered user handles and a control module. Complementing the atherectomy platform is the FreedomFlow Peripheral Guidewire, a stainless steel core-to-tip guidewire with silicone coating that received FDA clearance in June 2022. All products are designed, developed, and manufactured in the USA (Minnesota).

Differentiator

Problem solved

Functional benefit

Brands

  • FreedomFlow: FreedomFlow is an orbital atherectomy platform for treating peripheral artery disease (PAD). The platform uses diamond-coated spheres in a spiral geometry to clear plaque blockages in peripheral arteries, treating vessels from 2mm to 8mm in diameter.

Products and services

  • FreedomFlow Orbital Atherectomy Platform Catheter-based orbital atherectomy platform for treating peripheral artery disease (PAD) in hospitals, ambulatory surgery centers, and office-based labs. Uses diamond-coated spheres in a spiral geometry that creates a rotational vortex to sand away plaque blockages, treating vessels from 2 mm to 8 mm in diameter with a single device. Includes 5 Fr 3-sphere, 5 Fr 5-sphere, and 6 Fr 5-sphere driveshaft options, pneumatic and electric-powered user handles, and a control module with tubing set.
  • FreedomFlow Peripheral Guidewire Stainless steel core-to-tip peripheral guidewire with fixed distal-spring coil and silicone coating on the distal 200 cm. Designed to provide exceptional support for diagnostic and therapeutic devices used in treating plaque blockages in arteries both above and below the knee. The 0.014-inch core-to-tip design delivers superior torque transmission and precise control, enabling delivery of multiple interventional devices on a single guidewire.

Quantifiable outcome

  • Treats vessels from 2mm in the ankle to 8mm in the hip with a single device
  • +2 more outcomes

Companies that use Cardio Flow

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Cardio Flow technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Cardio Flow partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered key.

  • Cardiovascular Institute of the South (CIS)keyStrategic or Co-development Partner · 30 October 2023CIS performed the first commercial cases of the FreedomFlow Orbital Atherectomy Platform. Drs. Craig Walker, Pradeep Nair, and McCall Walker conducted the initial procedures on patients with complex arterial anatomy, multiple blockages, and extensive calcium including chronic total occlusions.
  • Advanced Cardiac & Vascular Centers for Amputation PreventionkeyStrategic or Co-development Partner · 2 June 2022Dr. Jihad Mustapha, Director and Chief Medical Officer of Cardio Flow, is also President and CEO of Advanced Cardiac & Vascular Centers for Amputation Prevention. The centers serve as a key clinical site for FreedomFlow device testing and the first commercial case with the peripheral guidewire was performed there by Dr. Mustapha.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Cardio Flow competitors and assessment

Company assessment

Direct peers

  • Avinger: Small-cap developer of lumivascular (OCT-guided) directional atherectomy (Pantheris, Tigereye) for PAD. Closely comparable in size, stage, and product focus to Cardio Flow, with similar U.S. sales channel.
  • Penumbra: Makes the Indigo CAT RX aspiration system and Lightning Bolt/Storm peripheral thrombectomy portfolio - an emerging direct competitor in the PAD/CLTI interventional space where Cardio Flow also operates.
  • Cardiovascular Systems (CSI): CSI pioneered orbital atherectomy with the Diamondback 360 and was acquired by Abbott in 2023. Cardio Flow's founders (Petrucci, Kallok) co-founded and led CSI, and FreedomFlow is the spiritual successor using a similar orbital mechanism - the closest possible direct peer.
  • Surmodics: Develops and commercializes peripheral vascular intervention products including drug-coated balloons and the Sublime guidewire line. Targets the same cath lab, ASC, and OBL sites of care as FreedomFlow.

Broad incumbents

  • AngioDynamics: Sells the Auryon atherectomy system (laser-based, acquired from Eximo Medical) within a broader vascular access and oncology portfolio. Direct competitor in peripheral atherectomy, particularly for below-the-knee lesions.
  • Medtronic: Through the HawkOne directional atherectomy system (acquired from Covidien/eV3) Medtronic is a leading player in peripheral atherectomy. Offers a much broader portfolio of PAD devices, with global reach Cardio Flow lacks.
  • Abbott Vascular: Acquired CSI in 2023 and now sells the Diamondback 360 orbital atherectomy line alongside a broad peripheral vascular portfolio (stents, balloons, closure). Competes head-to-head with FreedomFlow via the same mechanism Cardio Flow's founders originally commercialized.
  • Boston Scientific: Sells the Rotacarett rotational atherectomy system as part of a large peripheral vascular franchise (angioplasty balloons, stents, thrombectomy). Competes with FreedomFlow in U.S. cath labs and OBLs treating PAD.
  • Philips (Image-Guided Therapy): Markets laser atherectomy (formerly Spectranetics' Turbo-Elite and ExciLite) within a broad IGT/peripheral franchise. Competes with FreedomFlow in PAD/CLI procedures, especially where calcium modification is required.

Emerging players

  • Inari Medical: Focuses on venous thromboembolism and peripheral thrombectomy (FlowTriever, ClotTriever), increasingly expanding into arterial PAD/CLTI procedures. Adjacent competitor for the same interventional cardiologist and vascular surgeon customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Cardio Flow social profiles

Digital presence

Cardio Flow compliance and trust

Trust signal

Compliance2 records

Cardio Flow financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cardio Flow leadership team

Management profile

Number of profiles

Profiles6 records

Cardio Flow funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cardio Flow M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cardio Flow

What does Cardio Flow do?

Cardio Flow develops and sells the FreedomFlow Orbital Atherectomy Platform, a catheter-based system that uses diamond-coated spheres in a spiral geometry leveraging angular momentum physics to treat peripheral artery disease in vessels from 2 mm to 8 mm in diameter. The platform includes multiple driveshaft configurations (5 Fr 3-sphere, 5 Fr 5-sphere, and 6 Fr 5-sphere), pneumatic and electric-powered user handles, a control module, and the complementary FreedomFlow Peripheral Guidewire, targeting hospitals, ambulatory surgery centers, and office-based labs.

Is Cardio Flow a public or private company?

Cardio Flow is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Cardio Flow founded?

Cardio Flow was founded in 2010. It employs 11 to 50 people.

Where is Cardio Flow based?

Cardio Flow is headquartered in Saint Paul, United States, in the North America region.

How does Cardio Flow make money?

One revenue line is on record: freedomFlow Orbital Atherectomy Platform Sales.

Who are Cardio Flow's main competitors?

Direct peers on record are Avinger, Penumbra, Cardiovascular Systems (CSI) and Surmodics. Broad incumbents are AngioDynamics, Medtronic, Abbott Vascular, Boston Scientific and Philips (Image-Guided Therapy). Inari Medical is listed as an emerging player.

Does Cardio Flow have an API?

No public API is recorded for Cardio Flow.

What industry is Cardio Flow in?

Cardio Flow's product category is Peripheral Vascular Medical Devices. Its primary akta.pro industry code is HLAHAFAE, Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy).

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comKey Strategic Factors and Emerging Trends Shaping the Laser Atherectomy Devices Market LandscapeThe laser atherectomy devices market is projected to reach $1.98 billion by 2030, growing at a 9.0% CAGR, driven by rising demand for minimally invasive vascular treatments and advances in laser technology. In April 2023, Abbott Laboratories acquired Cardiovascular Systems Inc., expanding Abbott's vascular treatment portfolio with atherectomy technology for preparing vessels prior to angioplasty or stenting. Additionally, US-based Cardio Flow Inc. received FDA clearance in October 2023 for its FreedomFlow orbital atherectomy peripheral platform, designed to treat peripheral artery disease across a wide vessel diameter range.SecSEC FORM DCardio Flow, Inc. filed a Form D with the Securities and Exchange Commission on June 21, 2024, notifying regulators of an exempt securities offering under Rule 506(b). The company is raising up to $5 million in equity capital, having already sold $400,000 to three investors as of the filing date. This regulatory filing marks the formal initiation of a private fundraising round for the Minnesota-based health technology firm.SecSEC FORM DCardio Flow, Inc. filed a Form D with the Securities and Exchange Commission to announce an exempt offering of equity securities under Rule 506(b). The company is seeking to raise a total of $2,500,000 USD, having already sold $1,435,000 USD worth of securities to 12 investors as of May 16, 2023.SecSEC FORM DCardio Flow, Inc. filed a Form D with the Securities and Exchange Commission for an exempt offering of equity securities under Rule 506(b). The company is seeking to raise up to $2 million, having already sold $100,000 worth of securities as of September 1, 2023. The filing indicates a minimum investment threshold of $25,000 per investor.SecSEC FORM DCardio Flow, Inc. filed a Form D with the Securities and Exchange Commission to announce an exempt offering of securities under Rule 506(b). The company is seeking to raise a total of $12 million in equity capital, having already sold $200,000 worth of securities as of the filing date.SiliconprairienewsCardio Flow secures funding for device that removes plaque from arteries.Cardio Flow, Inc. secured $4.3 million in equity funding from an undisclosed angel investor in early June to support its First-in-Human clinical trials for the FreedomFlow™ Orbital Atherectomy device. The company aims to treat atherosclerosis by removing both calcified and fibrotic plaque from arteries of varying dimensions, including coronary and carotid vessels. This financing coincides with ongoing feasibility trials assessing the safety and efficacy of the device in peripheral vessels.